About George Simon
Board Certified in Medical Oncology
Pleural and Lung Cancer
Works for Specialty Center
Excellence in Research
Dr. George Simon joined MD Anderson in 2014, bringing years of experience treating patients with various thoracic diseases to the cancer center. He has a strong belief in the multidisciplinary, individualized approach to therapy.
Simon is a professor of medicine and section chief in the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson.
He served previously as assistant director of clinical research at the Medical University of South Carolina Hollings Cancer Center; director of thoracic oncology at the Fox Chase Cancer Center in Philadelphia; and as director of mesothelioma research at the H. Lee Moffitt Cancer Center in Tampa, Florida.
Simon works closely with thoracic surgeon Dr. David Rice and oncologist Dr. Anne Tsao in MD Anderson’s mesothelioma program, where patients are provided the latest, cutting-edge treatments.
As a leader in lung cancer research, he headed a clinical trial earlier in his career that led to the first treatment of the disease using gene therapy.
Simon’s research has centered on developing new, optimal mesothelioma treatments based on each patient’s molecular profile.
He has dedicated much of that research to understanding genetic predisposition for malignant pleural mesothelioma.
“Genetic predisposition for malignant pleural mesothelioma may play a strong role, such that even minimal or apparently inconsequential asbestos exposure may lead to tumor development,” he said.
Learn About COVID-19 and Mesothelioma
Get a free recording of the COVID-19 and mesothelioma presentation hosted by the experts at The Mesothelioma Center.Get Yours Now
Specialties of Dr. George Simon
Dr. George Simon’s Experience and Medical Education
Medical University of South Carolina Hollings Cancer Center
Fox Chase Cancer Center, Philadelphia
H. Lee Moffitt Cancer Center, Tampa
University of Colorado Health Science Center (Fellowship)
St. Joseph Hospital, Denver (Residency)
Christian Medical College, Vellore, India (Residency)
Awards and Other Recognitions
Castle Connolly Top Doctor Award
America’s Top Doctor Award
Houston’s Top Doctor Award
Mesothelioma Clinical Trials Under Dr. George Simon
A phase II clinical trial studying the immunotherapy combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for patients with rare tumors, including pleural mesothelioma.
A phase II clinical trial studying the use of treatment directed by genetic testing for patient with solid tumors or lymphomas that have progressed following standard of care treatment.
Publications of Dr. George Simon
Simon, G.R. et al. (2012). Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced non-small cell lung cancer: evidence from an individual patient analysis. Cancer.
Simon, G.R. (2011). Personalized lung cancer treatment based on molecular determinants. Journal of the South Carolina Medical Association.
Simon, G.R., Silvestri, G.A. (2011). You just can’t call it lung cancer anymore. Journal of Thoracic Oncology.
Disclaimer: Dr. George Simon has no professional affiliation with Asbestos.com.
1 Cited Article Sources
The sources on all content featured in The Mesothelioma Center at Asbestos.com include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.
- Charleston Business Journal. (2015, December 2). MUSC Center of Economic Excellence recruits lung cancer expert. Retrieved from: http://www.charlestonbusiness.com/news/35651-musc-center-of-economic-excellence-recruits-lung-cancer-expert?rss=0
How did this article help you?
What about this article isn’t helpful for you?
Did this article help you?
Share this article
Last Modified April 3, 2020